Twenty-four adult volunteers (15 females and 9 males) were assigned to infusion with either placebo or CCK-4 in a randomized, double-blind, parallel-group design, with EEG being recorded before and during (10 and 40 min) a 60-min infusion period.
In human studies in which lipopolysaccharide (LPS) was instilled into airways, there were decreased numbers of neutrophils in the airways among the volunteers randomly assigned to infusions of APC [ 3].
Of those, 37 subjects were randomly assigned to LCIG infusion plus placebo capsules and 34 subjects were randomly assigned to LC-oral plus placebo gel infusion.
At parturition, cows were assigned to abomasal infusion of water (CTRL) or casein (CAS).
Within each period, cows were assigned randomly to infusion site sequence: abomasum (A -cranial reticulorumen (R) or the reverse, R-A -cranial
Results The trial included 54 patients, of whom 27 were assigned to continuous infusion of hydrocortisone and 27 to discontinuous mode.
The volunteers were randomly assigned to either infusion with alanine-glutamine on the first trial day and placebo on the second (n = 5) or vice versa (n = 3).
However, the protocol was equally effective for patients randomly assigned to propofol infusion, prompting further questions about possible unrecognized benefits that accrue from complete interruption (reduced need for vasoactive drug, less fluid administration, and spontaneous muscle movement).
Diabetic and non-diabetic mice were randomly assigned for chronic infusion with either the DPP-4 resistant GLP-1 mimetic, exendin-4 (at a concentration employed in previous in vivo studies; 25 nmol/kg/day; GL Biochem, average purity 90%%) [ 34], or saline control via an osmotic minipump (Model 1004, Alzet, Cupertino, CA, USA) for either 4 or 8 weeks.
In ASSERT, patients were randomly assigned to receive infusions of placebo or 5 mg/kg infliximab at weeks 0, 2, 6, 12 and 18 and were allowed to receive concurrent NSAID but not DMARD or systemic corticosteroids.
In this phase II trial, 339 patients with active RA, despite methotrexate treatment, were randomly assigned to receive infusions of abatacept 2 mg/kg, abatacept 10 mg/kg, or placebo monthly for 6 months.
